The Cochlear Ltd (ASX: COH) share price is in focus today following a trading update that includes a reduction to the company's FY26 underlying net profit guidance and softer implant demand in developed markets.
Image source: Getty Images
What did Cochlear report?
- Second half FY26 sales growth now expected at 2–6% in constant currency (CC)
- FY26 underlying net profit guidance reduced to $290–330 million (was $435–460 million)
- Revenue for cochlear implants in developed markets flat for the recent quarter in CC
- Services revenue up 13% in the third quarter (CC); Acoustics revenue up 11% (CC)
- Additional FY26 profit impacts of up to $10 million (provisions for Middle East receivables), $20 million (lower gross margin), $18–25 million (cost base reshaping), and $25 million (FX impact after tax)
What else do investors need to know?
Softer trading in developed markets is being driven by hospital capacity constraints and a decline in referrals from the hearing aid channel, especially in the US and parts of Europe. Cochlear also faces growing uncertainty in the Middle East, with potential order cancellations and delayed deliveries due to regional conflict.
On a positive note, the company's services and acoustics segments continue to show strong revenue growth, aided by new product launches and an expanding installed base. Cochlear says it has a robust R&D pipeline and remains focused on investing in long-term growth, particularly in the adults and seniors segment.
What did Cochlear management say?
CEO and President Dig Howitt, said:
Addressing hearing loss in adults and seniors continues to be treated as a discretionary intervention, highlighting the importance of our strategy to medicalise hearing loss so that treatment is recognised as an important health priority.
We remain confident of our market leadership. We have seen strong adoption of the Nucleus® Nexa™ System across the developed markets, with very positive customer feedback and a strong interest in exploring the system's potential to further improve hearing outcomes. With contracting of the new system complete, market share has been improving.
What's next for Cochlear?
Cochlear plans to accelerate investment in the adults and seniors market and reshape its cost base to enable further growth. This includes reallocating resources towards strengthening referral pathways, enhancing commercial execution, and ongoing R&D for product innovation.
Despite near-term challenges, management says the company is positioned for long-term sustainable growth with a broad technology pipeline, including next-generation and totally implantable cochlear implants in regulatory trials.
Cochlear share price snapshot
Over the past 12 months, Cochlear shares have declined 35%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 15% over the same period.
